MedTrace Logo

Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

NCT04577742 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2020-10-08

No results posted yet for this study

Summary

This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020

Conditions

Interventions

RADIATION

106 Ruthenium plaque brachytherapy

All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-01
Primary Completion
2020-03-20
Completion
2020-03-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04577742 on ClinicalTrials.gov